⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 1, 2024VaccineOpen Access

Safety profile of recombinant adjuvanted anti-herpes zoster vaccine (RZV) in high-risk groups: Data from active surveillance program. Puglia (Italy), 2021–23

Pasquale Stefanizzi Lorenza Moscara Claudia Palmieri Andrea Martinelli Antonio Di Lorenzo Vincenzo Venerito Cinzia Germinario Silvio Tafuri

View Full Paper

Ask AI

Bookmark

Share

Abstract

Since 2021 a recombinant adjuvanted anti-Herpes Zoster vaccine(Recombinant Zoster Vaccine, RZV) is offered in Italy to high-risk patients. Few real-life data about RZV safety are available in target populations.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Stefanizzi et al. (2024) studied this question.

synapsesocial.com/papers/68e70d94b6db64358768729c https://doi.org/10.1016/j.vaccine.2024.03.024

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Effectiveness and Safety of Recombinant Zoster Vaccine in Rheumatic Diseases: Real-World Evidence from a Single-Centre Italian Cohort2025 · 5 citations
2Safety of Adjuvanted Recombinant Herpes Zoster Virus Vaccination in Fragile Populations: An Observational Real-Life Study2024 · 9 citations
3What is Different about Recombinant Herpes Zoster Vaccine?2024 · 3 citations
4Recombinant zoster vaccine in patients with inflammatory rheumatic diseases: efficacy, long-term protection and safety under immunosuppressionHuman Clinical Trial · 2026 · 3 citations
5Herpes zoster recurrence, and safety and immunogenicity of the recombinant zoster vaccine in adults aged ≥50 years with a history of herpes zoster: a phase 3, randomized controlled trial2025 · 4 citations

More related papers

Efficacy, reactogenicity, and safety of the adjuvanted recombinant zoster vaccine for the prevention of herpes zoster in Chinese adults ≥ 50 years: A randomized, placebo-controlled trial2024
Comparison of Vaccine Adverse Events Between Zoster Vaccine Live and Recombinant Zoster Vaccine: A Prospective Multicenter Survey2026
P0767Safety, Tolerability and RealWorld Effectiveness of Recombinant Zoster Vaccine (Shingrix®) in Patients with Inflammatory Bowel Disease: A Prospective SingleCentre Cohort2026

More from Vaccine

Timeliness of routine childhood vaccination in the Democratic Republic of the Congo: data from national vaccine surveys in 2021/2022, 2023 and 2024Sat,
Cost-effectiveness of universal infant hepatitis B vaccination programme in FinlandFri,